Author

R. Khoury

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:chromatin & epigenetic regulation· 1 Assay:protein structure· 1 Approach:statistical model· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

A. A. Bobkov· 1 shared A. Baidaliuk· 1 shared A. Ferrier· 1 shared A. L. Cooksy· 1 shared A.-L. Favier· 1 shared B. M. Conley· 1 shared C. D. Sohl· 1 shared C. Enfroy· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. A. Bobkov

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Active site remodeling in IDH1 mutants drives distinct kinetic and potential resistance mechanisms

M. Mealka, N. A. Sierra, D. A. Matteo, E. Albekioni, R. Khoury, T. Mai, B. M. Conley, N. J. Coleman, K. A. Sabo, E. A. Komives, A. A. Bobkov, A. L. Cooksy, S. Silletti, J. M. Schiffer, T. Huxford, C. D. Sohl

This study compares the reaction mechanisms of two IDH1 mutants, finding that R132Q has optimized active site conformation for both conventional and neomorphic activity, potentially explaining resistance to inhibitors.

bioRxiv · Jan 10, 2024Biochemistry

Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreak

G. Frenois-Veyrat, F. Gallardo, O. Gorge, E. Marcheteau, O. Ferraris, A. Baidaliuk, A.-L. Favier, C. Enfroy, X. Holy, J. Lourenco, R. Khoury, F. Nolent, D. W. Grosenbach, D. Hruby, A. Ferrier, , J.-N. Tournier

This study tests tecovirimat's efficacy against the 2022 MPXV outbreak strain, showing nanomolar activity compared to cidofovir's micromolar activity.

bioRxiv · Jul 19, 2022 · PreprintMicrobiology